TY - JOUR T1 - Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1023 LP - 1027 DO - 10.1136/annrheumdis-2021-221554 VL - 81 IS - 7 AU - David Simon AU - Koray Tascilar AU - Filippo Fagni AU - Katja Schmidt AU - Gerhard Krönke AU - Arnd Kleyer AU - Andreas Ramming AU - Verena Schoenau AU - Daniela Bohr AU - Johannes Knitza AU - Thomas Harrer AU - Karin Manger AU - Bernhard Manger AU - Georg Schett Y1 - 2022/07/01 UR - http://ard.bmj.com/content/81/7/1023.abstract N2 - Objectives To test whether patients with immune-mediated inflammatory disease (IMIDs), who did not respond to two doses of the SARS-CoV-2 vaccine, develop protective immunity, if a third vaccine dose is administered.Methods Patients with IMID who failed to seroconvert after two doses of SARS-CoV-2 vaccine were subjected to a third vaccination with either mRNA or vector-based vaccines. Anti-SARS-CoV-2 IgG, neutralising activity and T cell responses were assessed at baseline and 3 weeks after revaccination and also evaluated seprarately in rituximab (RTX) and non-RTX exposed patients.Results 66 non-responders were recruited, 33 treated with RTX, and 33 non-exposed to RTX. Overall, 49.2% patients seroconverted and 50.0% developed neutralising antibody activity. Seroconversion (78.8% vs 18.2%) and neutralising activity (80.0% vs 21.9%) was higher in non-RTX than RTX-treated patients with IMID, respectively. Humoral vaccination responses were not different among patients showing positive (59.3%) or negative (49.7%) T cell responses at baseline. Patients remaining on mRNA-based vaccines showed similar vaccination responses compared with those switching to vector-based vaccines.Conclusions Overall, these data strongly argue in favor of a third vaccination in patients with IMID lacking response to standard vaccination irrespective of their B cell status.Data are available on reasonable request. N/A. ER -